14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 3.503 2 days ( -2.87 % )
Last Price $2.87 2.87 %
High/ Low $2.82 - $2.99 34.04%
Chg 7 Days 34.74 % $2.13 $2.87
Chg 30 Days -6.21 % $3.06 $2.87
Chg 12 mos -3.69 % $2.98 $2.87
Trend - 3 mos -34.38 % Width: 78.44 %
Trend - 12 mos 31.61 % Width: 110.79 %
Pred. range - 3 mos $1.13 - $2.01 -60.78 % - -30.02 %
Pred. range - 12 mos $2.69 - $5.67 -6.21 % - 97.71 %
Short MA avg 3 mos Sell Apr 24, 2024 - 8 days
Long MA avg 3 mos Buy Apr 30, 2024 - 4 days
Short/Long MA avg 3 mos Sell Mar 12, 2024 - 38 days
Short MA avg 12 mos Buy Apr 30, 2024 - 4 days
Long MA avg 12 mos Buy Mar 27, 2024 - 27 days
Short/Long MA avg 12 mos Sell Apr 04, 2024 - 22 days
Pivot Short Buy Apr 18, 2024 - 12 days
Bollinger Buy Apr 15, 2024 - 15 days
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Poseida Therapeutics, Inc.

Poseida Therapeutics. Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patient... PSTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT